Nanobiotix S.A. EBIT

The latest EBIT for NANO.PA is $-70M as of June 2026. That compares with $-25M in the prior-year period — down 183.9% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Nanobiotix S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, NANO.PA's EBIT moved from $-25M to $-70M — a 183.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nanobiotix S.A.'s operating scale or balance-sheet position.

Against Healthcare companies, NANO.PA currently prints $-70M for EBIT, while the sector average sits near $130B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Nanobiotix S.A.'s growth, margins, and balance sheet.

A EBIT figure of $-70M for NANO.PA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting NANO.PA's EBIT ($-70M), review year-over-year change from $-25M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.